Leadership

UnitedHealth Group reported stronger-than-expected first-quarter earnings and raised its full-year outlook, signaling improving cost control and early progress in stabilizing performance.

Pfizer’s broad pipeline and recent acquisitions have yet to translate into a coherent market narrative, contributing to investor uncertainty during a critical period of strategic transition.

The Trump administration’s new executive order aims to accelerate FDA review of psychedelic therapies for mental health conditions, highlighting a potential shift in regulatory timelines and expanded access pathways,

Morten Graugaard, CEO, Orbis Medicines, discusses the importance of oral biologics and the industry impacts of FDA's approval of Icotyde.

Our April issue's feature profile offers a reminder that, increasingly, the CFO role in pharma is not just about stewardship but about shaping direction.

In becoming the first CFO to be named HBA Woman of the Year, AstraZeneca's Aradhana Sarin highlights how financial leadership now sits at the center of innovation, access and strategic transformation.

Shah Capital escalates its pressure campaign against Novavax leadership, requesting changes and strategic overhauls amid ongoing performance concerns.

Since the start of President Trump's second term, the FDA, CDC, CDER, and CBER have collectively cycled through more than a dozen leadership changes.

Mindsets must shift from increasing headcount to prioritizing competency-based training and systems.

Why balancing risk factors to foster breakthrough science remains one of the key challenges in R&D leaderships.

Eli Lilly warns that the UK's current framework is undermining investment and could impact future launches and manufacturing decisions.

Inside Consano Bio’s bet on first-in-class nerve repair—and what it takes to lead an early-stage biotech through uncertainty.

In this Pharmaceutical Executive Academy discussion, Najat Khan, PhD, CEO of Recursion Pharmaceuticals and former chief data science officer at J&J, explores the intersection of AI, pharma, and patient care — and the strategic pivots necessary to drive measurable and lasting gains across the value chain.

Bavarian Nordic CEO Paul Chaplin will step down by the end of 2026 after overseeing the company’s transformation into a profitable global vaccine player,

In today’s Pharmaceutical Executive Daily, Alkermes outlines its CEO succession plan following Richard Pops’ retirement announcement, leadership changes continue at Sarepta Therapeutics and Rivus Pharmaceuticals, and Boehringer Ingelheim secures an exclusive license for a preclinical small-molecule program.

Sarepta Therapeutics begins a CEO succession process, while Rivus Pharmaceuticals appoints a new chief executive to advance its late-stage pipeline in MASH, obesity, and cardiometabolic disease.

Alkermes announces that longtime CEO Richard Pops plans to step down on July 31, 2026, with his successor already set to step into the role on August 1.

HHS Secretary Robert F. Kennedy Jr. reorganized senior leadership at the department to streamline management and advance the administration’s health policy priorities.

From lessons in risk-taking—and building “from zero”—to career-defining pivots, Leonard Mazur, CEO of Citius Pharmaceuticals, reflects on 50-plus years in pharma.

Sanofi named Belén Garijo as its next CEO, signaling a leadership shift aimed at sharpening execution and R&D productivity as the company moves beyond the strategic overhaul of the past six years.

How to optimize a pharma location strategy in unheralded but rich regions for biotech talent around the world.

As precision medicine shifts from promise to practice, true patient impact will depend less on standalone drugs and more on whether pharma, MedTech, and diagnostics can finally converge to build integrated systems of care.

Inside Brent Saunders’ return run as CEO of Bausch + Lomb—and setting the storied eye care pharma on a bold path of reinvention.

The first wave of Commissioner’s National Priority Vouchers signals a fundamental shift in FDA competitiveness, rewarding companies that pair breakthrough science with affordability commitments, onshore manufacturing readiness, and the operational muscle to execute ultra-accelerated reviews.

A Q&A with Christopher Stanton, Ph.D., Marvin Bower Associate Professor of Business Administration at Harvard Business School.